Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CCXI $8.67 0.8700 +11.15%
VBLT $8.05 0.6700 +9.08%
FPRX $25.64 2.1200 +9.01%
ADXS $25.16 2.0400 +8.82%
AGEN $8.18 0.5600 +7.35%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GALT $2.51 -0.2300 -8.39%
BMY $64.60 -4.5500 -6.58%
BPTH $1.20 -0.0800 -6.25%
XBIT $19.12 -0.8000 -4.02%
GALE $1.57 -0.0600 -3.68%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

‘Safety Switch’ Kills Haywire Immune Cells in Transplant Test

(Bloomberg) May 14, 2015 - A “safety switch” drug by Bellicum Pharmaceuticals Inc. killed off overactive immune system cells in a study of transplant patients, raising hopes that the treatment can also be used to manage risks in an experimental class of cancer therapies.
read article 



Feds Say That in Screening Colonoscopies, Anesthesia Comes with No Charge

(Kaiser Health News) May 15, 2015 - Earlier this week the federal government clarified that insurers can’t charge people for anesthesia administered during a free colonoscopy to screen for colorectal cancer.
read article 



Embattled Scope Makers Won't Speak at FDA Superbug Hearing

(Los Angeles Times) May 14, 2015 - Olympus Corp. and two other manufacturers of medical scopes linked to a string of superbug outbreaks declined to speak Thursday at a Food and Drug Administration hearing on the deadly problem.
read article (free registration required) 



ASCO Cancer Research Data Drop: What to Watch

(CNBC) May 13, 2015 - The biotech investing world will be glued to their computers Wednesday afternoon.
read article 



Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts

(TheStreet) May 13, 2015 - The American Society of Clinical Oncology has provided public access to 5,000 cancer drug trial research abstracts ahead of its big annual meeting. These will be some highlights for investors.
read article 



Puma Biotechnology Founder Auerbach Loses $250 Million on Cancer Drug Data

(Forbes) May 13, 2015 - On Wednesday afternoon, Forbes estimated Puma Biotechnology Founder, Chairman, and Chief Executive Alan Auerbach’s net worth at $1.19 billion.
read article 



Takeda Dumps Late-Stage Lymphoma Drug on Trial Failure

(PharmaTimes [UK]) May 13, 2015 - Takeda has killed off a late stage programme assessing the potential of alisertib in lymphoma after interim analysis failed to show any benefit in progression-free survival.
read article 



Rosetta Genomics Launches Two Assays for Bladder Cancer

(MarketWatch) May 14, 2015 - Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular and other diagnostics, announces that the Company will commercially introduce two FGFR3 gene mutation assays; one for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive low-grade bladder cancers, and the other in conjunction with Ki67 expression for tissue-based prognostication at initial diagnosis of bladder cancer.
read article 



Smokers More Likely to Quit If Their Own Cash Is on the Line

(NPR/Shots blog) May 13, 2015 - A new study finds that employer-based programs to help people stop smoking would work better if they tapped into highly motivating feelings — such as the fear of losing money.
read article 



How DNA Sequencing Is Transforming the Hunt for New Drugs

(Reuters) May 13, 2015 - Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines.
read article 



RainTree Oncology Appoints Sriram Iyer President and CEO

(PharmiWeb.com) May 14, 2015 - RT Oncology Services Corporation the nation's leading community oncology alliance today announced the appointment of Sriram Iyer to the position of President and CEO to advance its strategy to improve cancer care through analytics and value-based care.
read article 



Heron Therapeutics Announces Positive Outcome from Meeting with FDA for HTX-019

(Yahoo! Finance) May 14, 2014 - Heron Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s proposal to use the 505(b)(2) development pathway for HTX-019, Heron’s proprietary intravenous formulation of aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV).
read article 



ASCO Appoints Lidia Schapira, MD, FASCO, Editor in Chief of Patient Information Website, Cancer.Net

(ASCO) May 14, 2015 - The American Society of Clinical Oncology (ASCO) has appointed Lidia Schapira, MD, FASCO, a medical oncologist at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, the new Editor in Chief of its award-winning patient information website, Cancer.Net.
read press release 



New Analysis of Cancer-Related Tweets Shows Emergence of Physician ‘Superusers’

(Yahoo! Finance) May 13, 2015 - Much of the conversation among physicians on Twitter about cancer is driven by a small number of doctors, according to a new analysis of digital behavior of U.S. physicians that found that the top 1 percent of physician Twitter users, by volume, contributed more than a third of all tweets about cancer during 2014.
read article 



10 Important Checkpoint Inhibitor Cancer Drug Abstracts from ASCO '15

(The Street) May 13, 2015 - For the past few years, the American Society of Clinical Oncology (ASCO) annual meeting has been dominated by cancer immunotherapy -- drugs which activate the body's own immune system to identify and kill cancer cells.
read article 



Stereotactic Ablative Radiotherapy Achieves Better Overall Survival Than Surgery for Early Lung Cancer

(MD Anderson) May 13, 2015 - Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care – invasive surgery – according to research from a phase III randomized international study from The University of Texas MD Anderson Cancer Center.
read press release 



'Too Toxic' Drug Revived for Metastatic Colorectal Cancer

(MedPage Today) May 13, 2015 - An international phase III trial has reported more than 2-month survival improvement in refractory metastatic colorectal cancer treated with TAS-102, an oral agent that combines trifluridine with tipiracil hydrochloride.
read article (free registration required) 



Tumor Sequencing Study Highlights Benefits of Profiling Healthy Tissue as Well

(MD Anderson) May 13, 2015 - As the practice of genetically profiling patient tumors for clinical treatment decision making becomes more commonplace, a recent study from The University of Texas MD Anderson Cancer Center suggests that profiling normal DNA also provides an important opportunity to identify inherited mutations that could be critical for patients and their families.
read press release 



Variations in Liver Cancer Attributable to Hepatitis Virus Variations

(MD Anderson) May 13, 2015 - Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease –hepatitis B virus (HBV) or hepatitis C virus (HCV).
read press release 



New Drug Combination Boosts Survival in Advanced Stomach and Esophageal

(Dana-Farber) May 14, 2015 - Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Scientists at Dana-Farber Cancer Institute, who led the research, will report these findings at the annual meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 1, 2015.
read press release 



Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015

(TheStreet) May 13, 2015 - Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced promising data supporting the ongoing clinical development program for lead compound onapristone to be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2 in Chicago, IL.
read article 



Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial

(Argos) May 13, 2015 - Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that more than 1,000 tumor samples have been collected and approximately 400 eligible patients have been randomized to the company's ongoing, pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC).
read corporate press release 



Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls

(MarketWatch) May 14, 2015 - Agenus Inc., an immunology company developing innovative treatments for cancers and other diseases, today announced that data on continuing survival from a Phase 2 study of its Prophage vaccine in glioblastoma multiforme (GBM) has been selected for an oral presentation at the 2015 ASCO Annual Meeting, to be held May 29 – June 2, 2015 in Chicago.
read article 



Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting

(StreetInsider) May 13, 2015 - Celldex Therapeutics, Inc. announced today that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
read article 



Threshold Announces Clinical Update on Evofosfamide in Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2015

(Yahoo! Finance) May 13, 2015 - Threshold Pharmaceuticals, Inc. today announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide (previously known as TH-302), an investigational compound, with bortezomib (Velcade®) and dexamethasone in patients with relapsed/refractory multiple myeloma.
read article